Division of Emerging and Transfusion Transmitted Diseases Bioterrorism Preparedness Initiatives Hira L. Nakhasi, Ph.D.

Slides:



Advertisements
Similar presentations
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Advertisements

Center for Biologics Evaluation and Research
Development of a Panel for Dengue Virus Maria Rios, PhD CBER/FDA Blood Products Advisory Committee Meeting December 14, 2010.
Utilizing a Non-Commercial Real- Time PCR to Detect HIV-1 RNA in HIV Antibody Negative Diagnostic Sera Submitted to The Maryland Public Health Laboratory.
Pediatric Diagnosis of HIV-1 Infection Using Dried Blood Spots Chin-Yih Ou, PhD NCHSTP/DHAP Centers for Disease Control and Prevention.
Development of Guidance Documents Jennifer Scharpf, M. P. H
Overview Division of Viral Products Office of Vaccines Research and Review Laboratory of Methods Development Site Visit January 9, 2003.
Overview of the Division of Viral Products
Introduction to Regulation
An Overview of Mission-related Research Office of Blood Research and Review C.D. Atreya, Ph.D. Associate Director for Research OBRR, CBER BPAC, Dec
CBER Regulatory Laboratory Planning & Preparedness for SARS-related Biologics Products Kathryn M. Carbone MD Associate Director for Research, Acting, Center.
Center for Biologics Evaluation and Research Applying Regulatory Science to Advance Development of Innovative, Safe and Effective Biologic Products Carolyn.
Overview of Terrorism Research at the CDC Dixie E. Snider, M.D., MPH. Associate Director for Science Presented at 2003 Medical Research Summit March 6,
Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.
Malaria Research Program at CBER Studies to improve Blood Safety from the risk of transfusion- transmitted malaria, and malaria pathogenesis and control.
Dengue Virus and Its Risk to the U.S. Blood Supply
CBER Cooperative Manufacturing Arrangements (Contractors) Jennifer Jones Consumer Safety Officer CBER, OBRR, DBA September 15, 2009.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
Microarrays: Basic Principle AGCCTAGCCT ACCGAACCGA GCGGAGCGGA CCGGACCGGA TCGGATCGGA Probe Targets Highly parallel molecular search and sort process based.
Classification of HLA Devices FDA Introduction & Background Sheryl A. Kochman CBER/OBRR/DBA.
Variants of PCR Lecture 4
HIV Testing Quality Assurance and Quality Control
A.Selvapandiyan LBPUA, OBRR, CBER, FDA, Bethesda, MD July Multiplex fluorescence-based PCR assay to detect pathogens in blood Multiplex fluorescence-based.
COBAS AmpliPrep/Cobas TaqMan HIV-1 Test
Topic 1. Validation of Procedures to Prevent Contamination and Cross-Contamination with TSE Agents of Human Tissue Intended for Transplantation TSEAC June.
BioLife Plasma Services Experience with HBV NAT Testing
Xenotropic Murine Leukemia Virus Related Virus (XMRV) Informational Presentation BPAC meeting, July 26, 2010 Indira Hewlett, Ph. D Chief, Laboratory of.
FDA’s Current Considerations of Parvovirus B19 Nucleic Acid Testing (NAT) Mei-ying W. Yu, PhD Division of Hematology CBER/FDA Extraordinary SoGAT Meeting.
Ensuring Product Quality in Gene Transfer Clinical Trials
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,
Overview of the Laboratory of Respiratory and Special Pathogens Michael Schmitt, Ph.D. Chief, Laboratory of Respiratory and Special Pathogens.
CE MARKING OF IVDDs - the NIBSC perspective Morag Ferguson Division of Virology.
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
Retrospective and Prospective U.S. Donor MRV Surveillance and Transmission Studies Michael Busch, MD, PhD Blood Systems Research Institute Dept of Laboratory.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Counter-terrorism at FDA Andrea Meyerhoff MD Director, Office of Counter-terrorism US Food and Drug Administration.
Yi-Chen Yang, Yu-Hsuan Chen, Show-Lan Chiu, Hwei-Fang Cheng Drug Biology Division, Bureau of Food and Drug Analysis Department of Health, Taiwan, ROC National.
HCV PCR By Henrietta Orji July 31 st, 2010 Hepatitis C Virus by Polymerase Chain Reaction.
Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
CBER’s Blood Safety Team Blood Products Advisory Committee 01 May 2008 Jonathan C. Goldsmith, MD Office of Blood Research and Review.
Center for Biologics Evaluation and Research Carolyn A. Wilson, Ph.D. Associate Director for Research Applying Regulatory Science to Advance Development.
1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.
Review of Site Visit Report Laboratory of Molecular Virology DETTD/OBRR/CBER March 18, 2005 Hira L. Nakhasi, Ph.D. Director, DETTD.
Update on FDA Workshop on Immune Globulins for Primary Immune Deficiency Diseases: Antibody Specificity, Potency and Testing Blood Products Advisory Committee.
Management of Donors and Units that Test HBV NAT Positive: Current Considerations July 21, 2005 BPAC Meeting Robin Biswas, M.D. FDA/CBER/OBRR/DETTD.
A. Discovery of New Genes related to Leishmania Pathogenesis and as Biomarkers of Attenuation Using a Genomic Microarray B. Multiplex PCR Microarray Assay.
TSE Clearance in Plasma Derivatives TSE Advisory Committee February 8, 2005 Dorothy Scott, M.D. DH/OBRR/CBER/FDA.
FDA’s Role in Facilitating the Availability of Influenza Vaccine Norman W. Baylor, Ph.D. Director, Office of Vaccines Research and Review CBER/FDA.
ANALYSIS OF GENE EXPRESSION DATA. Gene expression data is a high-throughput data type (like DNA and protein sequences) that requires bioinformatic pattern.
OBRR Response to BPAC Recommendations on the Office Research Program Office Site Visit: July 22, 2005 BPAC Recommendations: February 10, 2006 C.D. Atreya,
Office of Blood Research and Review Overview of Research Jay S. Epstein, M.D. Director, OBRR, CBER Blood Products Advisory Committee Meeting March 10,
Minimizing the Risks of TSE Agents in Human Tissues Melissa A. Greenwald, M.D. Division of Human Tissues Office of Cellular, Tissue and Gene Therapies;
Office of Vaccines Research and Review
Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.
Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
CBER Overview of Laboratory of Molecular Virology Indira Hewlett, Ph.D Laboratory Chief.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
Regulatory Guidance for Genetic Testing. Three Specific Areas Laboratory tests Results of genetic testing – Clinical – Research GenomeWide Association.
CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.
FDA Risk Management Strategy for Potential Exposure to vCJD from Plasma Derivatives TSE Advisory Committee December 15, 2006 Dorothy Scott, M.D. OBRR/CBER.
OCTGT Guidance Document Update Rachael Anatol, Ph.D. Associate Director for Policy-New Legislation February 26, 2014.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
West Nile Virus (WNV) and Donors of Human Cells, Tissues and Cellular and Tissue-Based Products (HCT/Ps) Melissa A. Greenwald, MD Division of Human Tissues.
Viro-chip Microarray Using a Pan-Viral Microarray Assay (Viro-chip) to Screen Clinical Samples for Viral Pathogens.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
Stanford University Dual Use Research of Concern in the Life Sciences
Presentation transcript:

Division of Emerging and Transfusion Transmitted Diseases Bioterrorism Preparedness Initiatives Hira L. Nakhasi, Ph.D.

Division of Emerging and Transfusion Transmitted Diseases (DETTD) Mission Plans and conducts basic and applied research –development, manufacture, pathogenesis and testing of Viral (HIV, HTLV, hepatitis), Parasitic, Bacterial, potential BT agents and Transmissible Spongiform Encephalopathy agents or “prions”. Ensures the safety of Nation’s blood supply – by reviewing, evaluating and recommending actions PLAs, PMAs, INDs, IDEs, 510(k)s for blood screening and diagnostic testing for above mentioned agents. Develops and revises FDA Guidance for users of blood screening and diagnostic products.

Division of Emerging and Transfusion Transmitted Diseases (DETTD) Mission Performs lot-release testing for approval of investigational tests and of licensed products. Develops reference materials for lot-release testing. Performs inspections of manufacturers of licensed products, manufacturing facilities. Provides expert scientific and technical advice to other Agency and Government components. Presents issues related to the safety and efficacy of blood donor screening testing at the Blood Product Advisory Committee and TSE Advisory Committee meetings

DETTD Strategic Plan to Counter Terrorism- policy and regulation –Donor screening/suitability Agent exposure (diagnostic or detection) Emergency release of blood components –Product Release Exemptions –Testing Sensitivity and Specificity

Actions to protect the blood supply DETTD-Policy –Use of ongoing and proposed vaccine trials to define the period of viremia/ bacteremia after vaccination –Development of a plan to vaccinate repeat donors –Consider whether immunosupressed blood recipients should get IG or antitoxins with transfusion

Regulation Test kit performance: Specificity  Clinical -Donor populations, e.g. intended use for blood and plasma donor testing  Analytical -Other diseases -Interference

Regulation Test kit performance: Sensitivity  Clinical –Known positives and high risk populations –Seroconversion panels –Variants  Analytical –Endpoint dilutions –Well characterized reference materials (WHO and CBER standards) Reproducibility –multiple sites, operators, kit lots

DETTD Strategic Plan to Counter Terrorism Actions to Protect the Blood Supply - Research –Detection and donor screening Microarray technology Nucleic Acid Testing –Pathogen Removal/Inactivation Tests for Blood and Blood products Tests for Plasma Derivatives –Pathogenesis of BT agents in blood

Actions to protect the blood supply DETTD Research Plan- short range plan I. Devise donor screening methods and tests to assure that affected individuals do not spread bioterrorism agents. –Adapt previously established nucleic acid based tests to detect BT agents in blood. –Develop primers and possibly probes for fluorogenic-based PCR for BT agents. –Collaborate with other agencies to test our reagents in their systems. –Encourage industry to submit INDs for serologic and nucleic acid based tests for blood screening and diagnosis.

Common Gene Amplification Chemistry Reverse Primer 5’ 5’ 3’ 5’ 3’ Forward Primer RQ 5’ 5’ 3’ 3’5’ 5’ 5’ Q R 5’ 3’ Fluorescent reporter and quencher dyes covalently linked to olignucleotide probe Nucleic Acid Template Reporter dye released during amplification. Reverse Primer 5’ 3’ Forward Primer

Actions to protect the blood supply - long range plan II. Investigate experimental testing methodologies to facilitate evaluation of industry methods. –For detection of several agents simultaneously –Development of a DNA oligonucleotide microarray for detection of bioweapon agents such as Variola major (Smallpox), Filoviruses, Yersinia pestis (Plague), Francisella tularensis (Tularemia), Bacillus anthracis (Anthrax) in blood and blood product based on their potential for transmission by blood during the asymptomatic incubation period.

Microarray as a Blood/BT Agent Diagnostic Tool HIVTAGGAATACCACATCCCGCA HCVACCCCCCCTCCCGGGAGAGC Leishmania.CTTTCCCATCGCAACTTCGGT T.cruzi TTTTGGGAGGGGCGTTCAAA PlagueCTTTCCGTGAGAAGACATCC B. anthracisGAACTCAAGAAAAAAGCGA SmallpoxACGACTCTCCATACGATGAT Pathogen sequences from databases AGCAGC CGGCGG G C T G A Synthesize probes, Print on microchip Extract genetic material from blood or blood products HIV genotyping array ( Lipshutz et al., Nat. Gen., 1999) Amplify and label the target with multiple, pathogen-specific primers Hybridize to microarray (hypothetical result)

Actions to protect the blood supply DETTD Research Plan- long range plan III. Develop antiviral compounds against viral BT agents capable of neutralizing and preventing viral growth. For in-vitro inactivation of BT agents in blood and blood products

Small-molecule microarray microarray Binding of Binding ofRNA-polymerase Addition of purified RNA-polymerase RNA-polymerase Detection of binding by plasmon resonance plasmon resonance Screening of small-molecules that bind to the Ebola virus RNA-dependent RNA-polymerase

DETTD Strategic Plan to Counter Terrorism Outcome: Develop laboratory expertise in new technologies Utilize this expertise for evaluation of related submissions from industry Transfer technology for industry development Lot-release testing Understand the molecular mechanisms of pathogenesis of BT agents in blood